BioSig launches AI development with Technion to discover the full range of ECG and intra-cardiac electrical signals

November 22, 2021 – BioSig Technologies Inc., a medical technology company that markets an innovative biomedical signal processing platform designed to improve signal fidelity and discover the full range of ECG and intracardiac signals, today announced that the Company has initiated a feasibility study with The Technion Foundation for Research and Development Ltd.

Based in Haifa, Israel, Technion – Israel Institute of Technology is a public research university offering degrees in science, engineering, and related fields, such as medicine, industrial management, and education. Over the years, the Technion has established itself as a leading academic institution in artificial intelligence (AI). It is currently ranked number one in AI in Europe and 15th in the world, with 100 faculty members engaged in fields across the AI ​​spectrum.

The feasibility program with BioSig will be led by Asst. Pr Joachim Behar, head of the artificial intelligence in medicine laboratory (AIMLab) at Technion. Under the terms of the program, ECG signals provided by the PURE EP system, the company’s signal processing technology for arrhythmia care, will be analyzed in the context of the development of AI-powered algorithms for atrial fibrillation ablation procedures.

“Artificial intelligence is quickly becoming a critical tool for increasing efficiency and generating value in many healthcare industries, but the predictive insights that form the basis of machine learning solutions depend on high data input. quality. Our clinical work provides us with vast volumes of smaller, often undetectable heart signals that contain additional diagnostic information, and we are excited to partner with Professor Behar and his Technion team to take our AI work to the next level. superior. Their expertise in developing deep learning systems for ECG recordings is invaluable to this program, and we look forward to reporting on the progress of this exciting new project, ”commented Kenneth L. Londoner, President and CEO by BioSig.

“The artificial intelligence laboratory in medicine [AIMLab.] at Technion focuses on the use of advanced signal processing and machine learning in medicine in the context of physiological time series analysis with particular emphasis in cardiology where we have 10 years of treatment expertise and ECG signal analysis. In particular, in our most recent research, we have developed robust deep learning algorithms for AF diagnosis and risk prediction by working on large databases, totaling over one million ECG records. . We look forward to bringing our expertise to support the industry leader in the field by providing new clinical ECG analysis tools. Our new partnership with BioSig is aligned with this desire to contribute and impact the medical field through AI-powered algorithms to support clinical decision making in cardiology, ”commented Asst. Professor Behar.

One in 18 Americans has a cardiac arrhythmia. Atrial fibrillation is the most common type of arrhythmia, affecting more than 33 million people worldwide, including more than 6 million in the United States. The number of people with atrial fibrillation is expected to reach 8 to 12 million by 2050.1 According to the Centers for Disease Control and Prevention (CDC), atrial fibrillation causes more than 750,000 hospitalizations in the United States each year, resulting in approximately $ 6 billion in health spending per year 2.

The PURE EP is an FDA approved 510 (k) Class II non-invasive device designed to improve the efficiency and effectiveness of cardiac electrophysiology procedures. To date, over 70 physicians have treated over 1,600 patient cases with the PURE EP System. Clinical data acquired by the PURE EP System in a multicenter study at the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Mayo Clinic Jacksonville, and Massachusetts General Hospital were recently published in the Journal of Cardiovascular Electrophysiology and are available as electronic with open access through the Wiley online library. Study results showed a 93% consensus among blinded reviewers with an overall improvement of 75% in intracardiac signal quality and confidence in the interpretation of PURE EP signals compared to conventional sources.

About the Technion – Israel Institute of Technology

Founded in 1912, the Technion-Israel Institute of Technology is Israel’s first university and its largest center for applied research. Technion is ranked among the leading technological universities in the world. A major source of innovation and brainpower that drives the Israeli economy, the Technion is the engine of Israel’s fame as an iconic “Startup Nation”. The people, ideas and inventions of the Technion have made and continue to make enormous scientific contributions in fields such as medicine, sustainable energy, computing, water conservation and nanotechnology. It is one of a handful of technological institutes around the world with a medical school, facilitating the rapid development of advanced therapies and devices, from the lab to the bedside.

Technion’s success is attributed to its unwavering commitment to excellence in teaching and research. The University is proud of its four Nobel Laureates – Aaron Ciechanover, Avram Hershko, Dan Shechtman and Arieh Warshel. Technion is currently tied with MIT for 8th place for the number of Nobel Laureates this century.
In 2011, the Technion and Cornell University joined forces to create an institution of applied science and engineering in New York: the Joan and Irwin Jacobs Technion Cornell Institute (JTCI). In 2013, Technion partnered with Shantou University to create the Guangdong Technion-Israel Institute of Technology (GTIT) in China.

The Technion Research and Development Foundation (TRDF) manages academic research programs and provides testing and research services for industry and government. T3, the technology transfer arm of TRDF, takes groundbreaking scientific ideas from the university and matches them with investors and entrepreneurs, licensing intellectual property and supporting the creation of start-ups.

About BioSig Technologies

BioSig Technologies is a medical technology company that markets a proprietary biomedical signal processing platform designed to improve signal fidelity and discover the full range of ECG and intracardiac signals.

The company’s first product, the Pure EP System is a computerized system for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing EKG and intracardiac signals for patients undergoing electrophysiology (EP) procedures. ) in an EP laboratory.

For more information:

Leave a Comment